Most of the studies are found at this link:
At the above link click on the names of all the doctors in the left hand column to see the studies
Ivermectin is an effective treatment for COVID-19. Treatment is more effective when used early. Meta analysis using the most serious outcome reported shows 66% [52‑76%] and 86% [75‑92%] improvement for early treatment and prophylaxis, with similar results after exclusion based sensitivity analysis (which excludes all of the GMK/BBC team studies), with primary outcomes, and after restriction to peer-reviewed studies or Randomized Controlled Trials. Statistically significant improvements are seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. 30 studies show statistically significant improvements in isolation. Results are very robust — in worst case exclusion sensitivity analysis 52 of 63 studies must be excluded to avoid finding statistically significant efficacy.
……………………………………
………………………………..
Ivermectin used in Health Care workers in India
https://pubmed.ncbi.nlm.nih.gov/33592050/
……………………………………..
Principia Scientific International “India Is Now Covid Free by Using Ivermectin” : https://principia-scientific.com/india-is-now-covid-19-free-by-using-ivermectin/
…………………………………………….
Ivermectin Wins in India https://wentworthreport.com/2021/09/11/ivermectin-wins-in-india/
……………………………………
India Could Sentence WHO Chief Scientist to Death for Misleading Over Ivermectin and Killing Indians. https://www.nextbigfuture.com/2021/06/india-could-sentence-who-chief-scientist-to-death-for-misleading-over-ivermectin-and-killing-indians.html?fbclid=IwAR07aOv5LvAj5xqWuw3Cu4d3lJSVm3CQupSSj7C8IzIJFc190KYZ7_LdXWc
…………………………………….
American Journal of Therapeutics : Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of Covid-19
…………………………………………….
The Emeritus Professor quoted ‘incredible meta-analyses, where serious statisticians have put all the studies together and come up with… …an 80% reduction in mortality in people using ivermectin – so conclusive that it was unethical to do further studies involving placebo patients.’
………………………………….
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248252/
Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
…………………….
https://pubmed.ncbi.nlm.nih.gov/34145166/
Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.
…………………………………….
https://pubmed.ncbi.nlm.nih.gov/33278625/
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
………………………………….
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088823/
Conclusions:
Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly reduced risks of contracting COVID-19 with the regular use of ivermectin. Finally, the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified.
……………………………….
A citywide initiative in Mexico City to prescribe ivermectin to COVID-19 patients resulted in a plunge in hospitalizations and deaths, two studies found.
Hospitalizations were down by as much as 76%, according to research by the Mexican Digital Agency for Public Innovation, Mexico’s Ministry of Health and the Mexican Social Security Institute, according to a TrialSiteNews report highlighted by LifeSiteNews.
Earlier this month, as WND reported, a significant decrease in cases in India coincided with the national health ministry’s promotion of ivermectin and hydroxychloroquine treatments.
In Mexico City, after a spike in cases in December, the city’s Ministry of Health created a home-treatment kit for residents. The city’s metro population is 22 million.
At the time, the head of the Mexico City Ministry of Health, Oliva López, said told reporters her agency had determined “that there is enough evidence to use in people positive for SARS-CoV-2, even without symptoms, some drugs such as ivermectin and azithromycin.”
Through a phone-call-based monitoring system and hospital data on admissions for COVID-19, the researchers found a reduction of between 52% and 76% in hospitalizations for those who took ivermectin compared to those who did not.
The government’s findings were corroborated by Dr. Juan J. Chamie-Quintero, a senior data analyst at private Colombian university EAFIT.
He found that excess deaths in the city dropped sharply only a few weeks after the ivermectin treatments began.
……………………………..
Doctor says 98% of 52 studies on Ivermectin show positive effect against COVID-19
………………………………
Dr Paul Marik
Credentials:
Trained in Medicine in South Africa, Critical care Fellowship in Ontario Canada, Admitted to Royal College of Medicine, Worked in various teaching hospitals, Board Certified in Critical Care Medicine, Internal Medicine, Neurocritical care, Nutritional Science,Full tenured professor of medicine in the USA, Written over 500 peer reviewed journal articles, 80 book chapters, Authored 40 critical books, Cited over 44,000 times in peer review publications, 350 lectures at international conferences, Founder of the Frontline Covid Critical Alliance, He Has developed effective treatment protocols for many diseases
Video of Dr Marik:
………………………………
Ivermectin Toxicity Review
https://ugetube.com/watch/ivermectin-toxicity-reviewed_jevFNIlsio8E6CU.html
………………………………..
Herbal and Alternative Medicine Uncensored 
IVM looks to be beneficial, but HCQ has better evidence, which you can see if you watch Dr. Harvey Risch’s video at
Risch is a professor of epidemiology at Yale and is extremely well regarded in his field. Risch has a PhD in biostatistics as well as a MD and explains studies very clearly. Risch provides lots of info that you won’t find anywhere else.
Why not both HCQ and IVM?
LikeLiked by 1 person